Lifeboat Foundation

A new biotech company co-founded by CRISPR pioneer Jennifer Doudna is developing a device that uses CRISPR to detect all kinds of diseases like malaria, tuberculosis, and Zika. The tech is still just in prototype phase, but research in the field is showing promising results. These CRISPR-based diagnostic tools have the potential to revolutionize how we test for diseases in the hospital, or even at home.

Called Mammoth Biosciences, the company is working on a credit card-sized paper test and smartphone app combo for disease detection. But the applications extend beyond that: The same technology could be used in agriculture, to determine what’s making animals sick or what sorts of microbes are found in soil, or even in the oil and gas industry, to detect corrosive microbes in pipelines, says Trevor Martin, the CEO of Mammoth Biosciences, who holds a PhD in biology from Stanford University. The company is focusing on human health applications first, however.

Continue reading “This company is making an at-home CRISPR kit to find out what’s making you sick” »

Health service chief calls for affordable access to CAR-T, which modifies immune system to destroy cancer cells.

Sarah Boseley Health editor.

Thu 26 Apr 2018 13.29 EDT Last modified on Thu 26 Apr 2018 17.00 EDT.

Continue reading “NHS preparing to offer ‘game-changing’ cancer treatment” »

Taking the supplement, dilation of subjects’ arteries improved by 42 percent, making their blood vessels, at least by that measure, look like those of someone 15 to 20 years younger. An improvement of that magnitude, if sustained, is associated with about a 13 percent reduction in heart disease, Rossman said. The study also showed that the improvement in dilation was due to a reduction in oxidative stress.

Older adults who take a novel antioxidant that specifically targets cellular powerhouses, or mitochondria, see age-related vascular changes reverse by the equivalent of 15 to 20 years within six weeks, according to new University of Colorado Boulder research.

The study, published this week in the American Heart Association journal Hypertension, adds to a growing body of evidence suggesting pharmaceutical-grade nutritional supplements, or nutraceuticals, could play an important role in preventing heart disease-the nation’s No. 1 killer. It also resurrects the notion that oral antioxidants, which have been broadly dismissed as ineffective in recent years, could reap measurable health benefits if properly targeted, the authors say.

Continue reading “Novel antioxidant makes old blood vessels seem young again” »

Elena Milova is at the Interventions to extend healthspan and lifespan 2018 conference in Kazan this week. This is an important conference in the aging research field, and it includes a variety of leading experts giving talks about their research. One of these experts is Andrei Gudkov, and Elena had the opportunity to talk with him about his research.

Dr. Andrei V. Gudkov, Ph.D., D.Sci, is a Scientific Co-Founder of Cleveland Biolabs, Inc. and has been its Chief Scientific Officer since June 2003. Dr. Gudkov serves as Chief Scientific Officer and Founder at Everon Biosciences, Inc. He co-founded Mega Biotech & Electronics Co., Ltd. and serves as its Chief Scientific Officer. Dr. Gudkov serves as Senior Vice President of Basic Science at Roswell Park Cancer Institute. He has over 25 years of experience in biomedical research. Prior to 1990, he worked with the National Cancer Research Center in Moscow (USSR), where he led a broad research program focused on virology and cancer drug resistance.

In 1990, he re-established his lab at the University of Illinois at Chicago, where he became a tenured faculty member in the Department of Molecular Genetics. In 1999, he defined p53 as a major determinant of cancer treatment side effects and suggested this protein as a target for therapeutic suppression. In 2001, Dr. Gudkov moved his laboratory to the Lerner Research Institute at the Cleveland Clinic Foundation, where he served as Chairman of the Department of Molecular Biology and Professor of Biochemistry at Case Western Reserve University. He has served as a Director of Cleveland Biolabs, Inc. since June 2003.

Continue reading “Interventions to extend healthspan and lifespan 2018- Dr. Andrei Gudkov” »

The ability to perform simple daily tasks can make a big difference in people’s lives, especially for those with spinal cord injuries. A UCLA-led team of scientists reports that six people with severe spinal cord injuries—three of them completely paralyzed—have regained use of their hands and fingers for the first time in years after undergoing a nonsurgical, noninvasive spinal stimulation procedure the researchers developed.

At the beginning of the study, three of the participants could not move their fingers at all, and none could turn a doorknob with one hand or twist a cap off a plastic water bottle. Each of them also had great difficulty using a cellphone. After only eight researcher-led training sessions with the spinal stimulation, all six individuals showed substantial improvements. The study participants had chronic and severe paralysis for more than one year, and some for more than 10 years.

From before the first session to the end of the last session, the participants improved their grip strength.

Continue reading “Noninvasive spinal stimulation method enables paralyzed people to regain use of hands, study finds” »

Hard to believe but some people are worried that when rejuvenation biotechnology is available they may be forced to use it.

Might rejuvenation become an imposition?

Suppose that, on a nice day not too far into the future, while everything is going reasonably well in your life and you are enjoying yourself, you walk into the doctor’s office for a regular checkup. The doctor finds nothing wrong with you, but in order to minimize your risk of developing diseases that are likely to strike people in your age range, she recommends that you undergo senolytic treatment. The treatment is safe, with no serious adverse effects, it is administered simply through injections, and it is either state-subsidized or otherwise affordable. In your opinion, what are the odds that you would refuse the doctor’s prescription and say that you’d rather take the risk of getting sick?

Continue reading “Some People Worry if Rejuvenation is Available they May be Forced to Use it” »

Detailed images of the anti-ageing enzyme telomerase are a drug designer’s dream.

A team of researchers, including professor Steve Horvath, the pioneer of the epigenetic clock, report in this new paper about an improved version of that clock [1]. His original epigenetic clock measures the age of a person by looking at DNA methylation patterns; these patterns correlate closely with the actual age of a person, with a margin of error of around two years or so.

Since the original clock was first created, work has continued on refining the process and how aging is measured. In terms of aging biomarkers, it is generally considered the gold standard, given how reliable it is as a way to determine biological age.

While chronological age is linked to the likelihood of us developing age-related diseases and dying, it is important to distinguish the difference between chronological age and biological age. Individuals of the same chronological age may not age in quite the same way or even at the same rate, showing differences in their susceptibility to different age-related diseases.

An interview from the recent Ending Aging conference in Berlin with Keith Comito which we did in collaboration with Anna Dobryukha from Komsomolskaya Pravda.

The Undoing Aging conference, a collaboration between the SENS Research Foundation and Michael Greve’s Forever Healthy Foundation, took place on March 15–17 in Berlin, which saw many researchers, advocates, investors, and other important members of the longevity community gather together to learn about the latest progress in rejuvenation biotechnology.

As we had arranged a travel grant for Anna Dobryukha, one of the best Russian journalists writing about aging, longevity, and rejuvenation research, to join us, it made sense to collaborate with her on the most interesting interviews. Anna works for Komsomolskaya Pravda, one of the largest Russian publishing houses, which has a newspaper, a radio station, and a website with over 40 million readers. Anna has also published an article based on this and other interviews taken during the conference which you can find here.

Continue reading “Undoing Aging with Keith Comito” »